Systemic Lupus Erythematosus: New Diagnostic and Therapeutic Approaches

Literature Cited

1. 1.

   Sirobhushanam S, Lazar S, Kahlenberg JM. 2021. Interferons in systemic lupus erythematosus. Rheum. Dis. Clin. North Am. 47:297–315
   [Google Scholar]
2. 2.

   Arbuckle MR, McClain MT, Rubertone MV et al. 2003. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349:1526–33
   [Google Scholar]
3. 3.

   Rees F, Doherty M, Lanyon P et al. 2017. Early clinical features in systemic lupus erythematosus: Can they be used to achieve earlier diagnosis? A risk prediction model. Arthritis Care Res. 69:833–41
   [Google Scholar]
4. 4.

   Drenkard C, Lim SS. 2019. Update on lupus epidemiology: advancing health disparities research through the study of minority populations. Curr. Opin. Rheumatol. 31:689–96
   [Google Scholar]
5. 5.

   Chan EK, Damoiseaux J, de Melo Cruvinel W et al. 2016. Report on the second International Consensus on ANA Pattern (ICAP) workshop in Dresden; 2015. Lupus 25:797–804
   [Google Scholar]
6. 6.

   Pisetsky DS. 2017. Antinuclear antibody testing—misunderstood or misbegotten?. Nat. Rev. Rheumatol. 13:495–502
   [Google Scholar]
7. 7.

   Agmon-Levin N, Damoiseaux J, Kallenberg C et al. 2014. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann. Rheum. Dis. 73:17–23
   [Google Scholar]
8. 8.

   Satoh M, Chan EK, Ho LA et al. 2012. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum 64:2319–27
   [Google Scholar]
9. 9.

   Abeles AM, Abeles M. 2013. The clinical utility of a positive antinuclear antibody test result. Am. J. Med. 126:342–48
   [Google Scholar]
10. 10.

    Li QZ, Karp DR, Quan J et al. 2011. Risk factors for ANA positivity in healthy persons. Arthritis Res. Ther. 13:R38
    [Google Scholar]
11. 11.

    Mahler M, Hanly JG, Fritzler MJ. 2012. Importance of the dense fine speckled pattern on HEp-2 cells and anti-DFS70 antibodies for the diagnosis of systemic autoimmune diseases. Autoimmun. Rev. 11:642–45
    [Google Scholar]
12. 12.

    Mariz HA, Sato EI, Barbosa SH et al. 2011. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum 63:191–200
    [Google Scholar]
13. 13.

    Pisetsky DS. 2016. Anti-DNA antibodies—quintessential biomarkers of SLE. Nat. Rev. Rheumatol. 12:102–10
    [Google Scholar]
14. 14.

    Damoiseaux J, Andrade LEC, Carballo OG et al. 2019. Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA Patterns (ICAP) perspective. Ann. Rheum. Dis. 78:879–89
    [Google Scholar]
15. 15.

    Aringer M, Costenbader K, Daikh D et al. 2019. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 71:1400–12
    [Google Scholar]
16. 16.

    Suda M, Kishimoto M, Ohde S, Okada M. 2020. Validation of the 2019 ACR/EULAR classification criteria of systemic lupus erythematosus in 100 Japanese patients: a real-world setting analysis. Clin. Rheumatol. 39:1823–27
    [Google Scholar]
17. 17.

    Abdwani R, Al Masroori E, Abdullah E et al. 2021. Evaluating the performance of ACR, SLICC and EULAR/ACR classification criteria in childhood onset systemic lupus erythematosus. Pediatr. Rheumatol. 19:141
    [Google Scholar]
18. 18.

    Alexander RV, Rey DS, Conklin J et al. 2021. A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus. Lupus Sci. Med. 8:e000528
    [Google Scholar]
19. 19.

    Putterman C, Furie R, Ramsey-Goldman R et al. 2014. Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. Lupus Sci. Med. 1:e000056
    [Google Scholar]
20. 20.

    Hui-Yuen JS, Gartshteyn Y, Ma M et al. 2018. Cell-bound complement activation products (CB-CAPs) have high sensitivity and specificity in pediatric-onset systemic lupus erythematosus and correlate with disease activity. Lupus 27:2262–68
    [Google Scholar]
21. 21.

    Ramsey-Goldman R, Alexander RV, Massarotti EM et al. 2020. Complement activation in patients with probable systemic lupus erythematosus and ability to predict progression to American College of Rheumatology-classified systemic lupus erythematosus. Arthritis Rheumatol 72:78–88
    [Google Scholar]
22. 22.

    Arriens C, Alexander RV, Narain S et al. 2020. Cell-bound complement activation products associate with lupus severity in SLE. Lupus Sci. Med. 7:e000377
    [Google Scholar]
23. 23.

    Munroe ME, Lu R, Zhao YD et al. 2016. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann. Rheum. Dis. 75:2014–21
    [Google Scholar]
24. 24.

    Li QZ, Zhou J, Lian Y et al. 2010. Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes. Clin. Exp. Immunol. 159:281–91
    [Google Scholar]
25. 25.

    Fanouriakis A, Kostopoulou M, Alunno A et al. 2019. 2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann. Rheum. Dis. 78:736–45
    [Google Scholar]
26. 26.

    Dima A, Jurcut C, Chasset F et al. 2022. Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Ther. Adv. Musculoskelet. Dis. 14:1759720X211073001
    [Google Scholar]
27. 27.

    Almeida-Brasil CC, Hanly JG, Urowitz M et al. 2022. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann. Rheumat. Dis. 81:370–78
    [Google Scholar]
28. 28.

    Shinjo SK, Bonfá E, Wojdyla D et al. 2010. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum 62:855–62
    [Google Scholar]
29. 29.

    Petri M, Konig MF, Li J, Goldman DW. 2021. Association of higher hydroxychloroquine blood levels with reduced thrombosis risk in systemic lupus erythematosus. Arthritis Rheumatol 73:997–1004
    [Google Scholar]
30. 30.

    Shipman WD, Vernice NA, Demetres M, Jorizzo JL. 2020. An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: a systematic review. J. Am. Acad. Dermatol. 82:709–22
    [Google Scholar]
31. 31.

    Lambers WM, Westra J, Bootsma H, de Leeuw K. 2021. Hydroxychloroquine suppresses interferon-inducible genes and B cell activating factor in patients with incomplete and new-onset systemic lupus erythematosus. J. Rheumatol. 48:847–51
    [Google Scholar]
32. 32.

    Olsen NJ, McAloose C, Carter J et al. 2016. Clinical and immunologic profiles in incomplete lupus erythematosus and improvement with hydroxychloroquine treatment. Autoimmune Dis 2016:8791629
    [Google Scholar]
33. 33.

    Balevic SJ, Weiner D, Clowse MEB et al. 2022. Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes. Lupus Sci. Med. 9:e000602
    [Google Scholar]
34. 34.

    Izmirly P, Kim M, Friedman DM et al. 2020. Hydroxychloroquine to prevent recurrent congenital heart block in fetuses of anti-SSA/Ro-positive mothers. J. Am. Coll. Cardiol. 76:292–302
    [Google Scholar]
35. 35.

    Rosenbaum JT, Costenbader KH, Desmarais J et al. 2021. American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 joint statement on hydroxychloroquine use with respect to retinal toxicity. Arthritis Rheumatol 73:908–11
    [Google Scholar]
36. 36.

    Petri M, Elkhalifa M, Li J et al. 2020. Hydroxychloroquine blood levels predict hydroxychloroquine retinopathy. Arthritis Rheumatol 72:448–53
    [Google Scholar]
37. 37.

    Illei GG, Austin HA, Crane M et al. 2001. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann. Intern. Med. 135:248–57
    [Google Scholar]
38. 38.

    Ugarte-Gil MF, Mak A, Leong J et al. 2021. Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Sci. Med. 8:e000590
    [Google Scholar]
39. 39.

    Apostolopoulos D, Kandane-Rathnayake R, Louthrenoo W et al. 2020. Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study. Lancet Rheumatol 2:e24–e30
    [Google Scholar]
40. 40.

    Borucki R, Werth VP. 2020. Expert perspective: an evidence-based approach to refractory cutaneous lupus erythematosus. Arthritis Rheumatol 72:1777–85
    [Google Scholar]
41. 41.

    Sakthiswary R, Suresh E. 2014. Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy. Lupus 23:225–35
    [Google Scholar]
42. 42.

    Carrión-Barberà I, Polino L, Mejía-Torres M et al. 2022. Leflunomide: a safe and effective alternative in systemic lupus erythematosus. Autoimmun. Rev. 21:102960
    [Google Scholar]
43. 43.

    Olivieri G, Ceccarelli F, Natalucci F et al. 2021. Five-years drug survival of mycophenolate mofetil therapy in patients with systemic lupus erythematosus: comparison between renal and non-renal involvement. Joint Bone Spine 88:105246
    [Google Scholar]
44. 44.

    McCune WJ, Golbus J, Zeldes W et al. 1988. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N. Engl. J. Med. 318:1423–31
    [Google Scholar]
45. 45.

    Houssiau FA, Vasconcelos C, D'Cruz D et al. 2002. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46:2121–31
    [Google Scholar]
46. 46.

    Askanase AD, Byron M, Keyes-Elstein LL et al. (ACCESS Trial Group). 2014. Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study. Arthritis Rheumatol 66:3096–104
    [Google Scholar]
47. 47.

    Appel GB, Contreras G, Dooley MA et al. 2009. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol. 20:1103–12
    [Google Scholar]
48. 48.

    Furie R, Rovin BH, Houssiau F et al. 2020. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N. Engl. J. Med. 383:1117–28
    [Google Scholar]
49. 49.

    Park DJ, Kang JH, Lee KE et al. 2019. Efficacy and safety of mycophenolate mofetil and tacrolimus combination therapy in patients with lupus nephritis: a nationwide multicentre study. Clin. Exp. Rheumatol. 37:89–96
    [Google Scholar]
50. 50.

    Rovin BH, Teng YKO, Ginzler EM et al. 2021. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397:2070–80
    [Google Scholar]
51. 51.

    Mok CC, Ho LY, Ying SKY et al. 2020. Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis. Ann. Rheum. Dis. 79:1070–76
    [Google Scholar]
52. 52.

    Navarra SV, Guzmán RM, Gallacher AE et al. 2011. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377:721–31
    [Google Scholar]
53. 53.

    Furie R, Petri M, Zamani O et al. 2011. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63:3918–30
    [Google Scholar]
54. 54.

    Zhang F, Bae SC, Bass D et al. 2018. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann. Rheum. Dis. 77:355–63
    [Google Scholar]
55. 55.

    Stohl W, Schwarting A, Okada M et al. 2017. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol 69:1016–27
    [Google Scholar]
56. 56.

    Singh JA, Shah NP, Mudano AS. 2021. Belimumab for systemic lupus erythematosus. Cochrane Database Syst. Rev. 2:CD010668
    [Google Scholar]
57. 57.

    Strand V, Berry P, Lin X et al. 2019. Long-term impact of belimumab on health-related quality of life and fatigue in patients with systemic lupus erythematosus: six years of treatment. Arthritis Care Res. 71:829–38
    [Google Scholar]
58. 58.

    Furie R, Rovin BH, Houssiau F et al. 2020. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N. Engl. J. Med. 383:1117–28
    [Google Scholar]
59. 59.

    Leandro MJ, Cambridge G, Edwards JC et al. 2005. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology 44:1542–45
    [Google Scholar]
60. 60.

    Lu TY, Ng KP, Cambridge G et al. 2009. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 61:482–87
    [Google Scholar]
61. 61.

    Merrill JT, Neuwelt CM, Wallace DJ et al. 2010. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab trial. Arthritis Rheum 62:222–33
    [Google Scholar]
62. 62.

    Rovin BH, Furie R, Latinis K et al. 2012. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64:1215–26
    [Google Scholar]
63. 63.

    Riggs JM, Hanna RN, Rajan B et al. 2018. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci. Med. 5:e000261
    [Google Scholar]
64. 64.

    Furie R, Khamashta M, Merrill JT et al. 2017. Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol 69:376–86
    [Google Scholar]
65. 65.

    Furie RA, Morand EF, Bruce IN et al. 2019. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol 1:e208–e219
    [Google Scholar]
66. 66.

    Morand EF, Furie R, Tanaka Y et al. 2020. Trial of anifrolumab in active systemic lupus erythematosus. N. Engl. J. Med. 382:211–21
    [Google Scholar]
67. 67.

    Furie R, Morand EF, Askanase AD et al. 2021. Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. Lupus 30:1254–63
    [Google Scholar]
68. 68.

    Heo YA. 2021. Voclosporin: first approval. Drugs 81:605–10
    [Google Scholar]
69. 69.

    Rovin BH, Solomons N, Pendergraft WF et al. 2019. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int 95:219–31
    [Google Scholar]
70. 70.

    Saxena A, Mela C, Coeshall A. 2021. Voclosporin for lupus nephritis: interim analysis of the AURORA 2 extension study. Arthritis Rheumatol 73:Suppl. 101425 (Abstr.)
    [Google Scholar]
71. 71.

    Mok CC. 2019. The Jakinibs in systemic lupus erythematosus: progress and prospects. Expert Opin. Investig. Drugs 28:85–92
    [Google Scholar]
72. 72.

    Furie R, Werth VP, Merola JF et al. 2019. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J. Clin. Investig. 129:1359–71
    [Google Scholar]
73. 73.

    Robinson S, Thomas R. 2021. Potential for antigen-specific tolerizing immunotherapy in systematic lupus erythematosus. Front. Immunol. 12:654701
    [Google Scholar]
74. 74.

    Ruiz-Irastorza G, Egurbide MV, Olivares N et al. 2008. Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology 47:920–23
    [Google Scholar]
75. 75.

    Mok CC. 2013. Vitamin D and systemic lupus erythematosus: an update. Expert Rev. Clin. Immunol. 9:453–63
    [Google Scholar]
76. 76.

    Lima GL, Paupitz J, Aikawa NE et al. 2016. Vitamin D supplementation in adolescents and young adults with juvenile systemic lupus erythematosus for improvement in disease activity and fatigue scores: a randomized, double-blind, placebo-controlled trial. Arthritis Care Res. 68:91–98
    [Google Scholar]
77. 77.

    Piantoni S, Andreoli L, Allegri F et al. 2012. Low levels of vitamin D are common in primary antiphospholipid syndrome with thrombotic disease. Reumatismo 64:307–13
    [Google Scholar]
78. 78.

    Andreoli L, Piantoni S, Dall'Ara F et al. 2012. Vitamin D and antiphospholipid syndrome. Lupus 21:736–40
    [Google Scholar]
79. 79.

    Petri M, Bello KJ, Fang H, Magder LS. 2013. Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio. Arthritis Rheum 65:1865–71
    [Google Scholar]
80. 80.

    Athanassiou L, Kostoglou-Athanassiou I, Tsakiridis P et al. 2022. Vitamin D levels in Greek patients with systemic lupus erythematosus. Lupus 31:125–32
    [Google Scholar]
81. 81.

    Fava A, Petri M. 2019. Systemic lupus erythematosus: diagnosis and clinical management. J. Autoimmun. 96:1–13
    [Google Scholar]
82. 82.

    van der Meulen TA, Harmsen HJM, Vila AV et al. 2019. Shared gut, but distinct oral microbiota composition in primary Sjögren's syndrome and systemic lupus erythematosus. J. Autoimmun. 97:77–87
    [Google Scholar]
83. 83.

    Hevia A, Milani C, López P et al. 2014. Intestinal dysbiosis associated with systemic lupus erythematosus. mBio 5:e01548–14
    [Google Scholar]
84. 84.

    Yamamoto EA, Jørgensen TN. 2019. Relationships between vitamin D, gut microbiome, and systemic autoimmunity. Front. Immunol. 10:3141
    [Google Scholar]
85. 85.

    Zegarra-Ruiz DF, El Beidaq A, Iniguez AJ et al. 2019. A diet-sensitive commensal lactobacillus strain mediates TLR7-dependent systemic autoimmunity. Cell Host Microbe 25:113–27.e6
    [Google Scholar]
86. 86.

    Mu Q, Tavella VJ, Kirby JL et al. 2017. Antibiotics ameliorate lupus-like symptoms in mice. Sci. Rep. 7:13675
    [Google Scholar]
87. 87.

    Pocovi-Gerardino G, Correa-Rodríguez M, Callejas-Rubio JL et al. 2021. Beneficial effect of Mediterranean diet on disease activity and cardiovascular risk in systemic lupus erythematosus patients: a cross-sectional study. Rheumatology 60:160–69
    [Google Scholar]
88. 88.

    Charoenwoodhipong P, Harlow SD, Marder W et al. 2020. Dietary omega polyunsaturated fatty acid intake and patient-reported outcomes in systemic lupus erythematosus: the Michigan lupus epidemiology and surveillance program. Arthritis Care Res. 72:874–81
    [Google Scholar]
89. 89.

    Zamansky GB. 1985. Sunlight-induced pathogenesis in systemic lupus erythematosus. J. Investig. Dermatol. 85:179–80
    [Google Scholar]
90. 90.

    Stege H, Budde MA, Grether-Beck S, Krutmann J 2000. Evaluation of the capacity of sunscreens to photoprotect lupus erythematosus patients by employing the photoprovocation test. Photodermatol. Photoimmunol. Photomed. 16:256–59
    [Google Scholar]
91. 91.

    Estadt SN, Maz MP, Musai J, Kahlenberg JM. 2022. Mechanisms of photosensitivity in autoimmunity. J. Investig. Dermatol. 142:849–56
    [Google Scholar]
92. 92.

    Kuhn A, Gensch K, Haust M et al. 2011. Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study. J. Am. Acad. Dermatol. 64:37–48
    [Google Scholar]
93. 93.

    Abdul Kadir WD, Jamil A, Shaharir SS et al. 2018. Photoprotection awareness and practices among patients with systemic lupus erythematosus and its association with disease activity and severity. Lupus 27:1287–95
    [Google Scholar]
94. 94.

    Al Sawah S, Zhang X, Zhu B et al. 2015. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus—the Hopkins Lupus Cohort. Lupus Sci. Med. 2:e000066
    [Google Scholar]
95. 95.

    Thamer M, Hernán MA, Zhang Y et al. 2009. Prednisone, lupus activity, and permanent organ damage. J. Rheumatol. 36:560–64
    [Google Scholar]
96. 96.

    Gladman DD, Urowitz MB, Rahman P et al. 2003. Accrual of organ damage over time in patients with systemic lupus erythematosus. J. Rheumatol. 30:1955–59
    [Google Scholar]
97. 97.

    Condon MB, Ashby D, Pepper RJ et al. 2013. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann. Rheum. Dis. 72:1280–86
    [Google Scholar]
98. 98.

    Barber MRW, Drenkard C, Falasinnu T et al. 2021. Global epidemiology of systemic lupus erythematosus. Nat. Rev. Rheumatol. 17:515–32
    [Google Scholar]
99. 99.

    Gandelman JS, Khan OA, Shuey MM et al. 2020. Increased incidence of resistant hypertension in patients with systemic lupus erythematosus: a retrospective cohort study. Arthritis Care Res. 72:534–43
    [Google Scholar]
100. 100.

     Singh RR, Yen EY 2018. SLE mortality remains disproportionately high, despite improvements over the last decade. Lupus 27:1577–81
     [Google Scholar]
101. 101.

     Martz CD, Allen AM, Fuller-Rowell TE et al. 2019. Vicarious racism stress and disease activity: the Black Women's Experiences Living with Lupus (BeWELL) study. J. Racial Ethn. Health Disparities 6:1044–51
     [Google Scholar]
102. 102.

     Minhas D, Marder W, Harlow S et al. 2021. Access and cost-related nonadherence to prescription medications among lupus patients and controls: the Michigan Lupus Epidemiology and Surveillance program. Arthritis Care Res. 73:1561–67
     [Google Scholar]